Virtual Library

Start Your Search

Eva Richterov√°



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC) (ID 464)

      12:30 - 13:00  |  Author(s): Eva Richterov√°

      • Abstract
      • Slides

      Background

      Complex network of chemokines is a part of immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is not clear whether the concentrations of chemokines at the time of diagnosis of NSCLC reflect extent of the disease. Aim: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in plasma of patients with resectable NSCLC to those without cancer. To find out whether the chemokine concentrations differ according to stage of the disease.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      We enrolled 69 patients undergoing surgery for proven/suspected NSCLC (37 males- mean age 66 years, 32 females- mean age 64 years). They underwent standard diagnostic and staging procedure to determine resectability (CT/PET-CT, bronchoscopy, ev. abdominal ultrasound), then surgery was made. We diagnosed 42 patients with NSCLC, 27 patients in the control group had benign lung pathologies (e.g. chondrohamatoma, fibrous tissue) and remained as the control group. We took plasma samples before surgery in treatment naive patients. The chemokine concentrations were assesed by ELISA LSBio Kits. The results were stated in pg/ml (CCL2, CCL8), ng/ml (CXCL12). Parametric statistics was used for results analysis.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      CCL2 (pg/ml)pCCL8 (pg/ml)PCXCL12 (ng/ml)p
      NSCLC/benign lesions169,09/146,590,34556,22/48,840,4866,32/5,30,204
      NSCLCst. I/ benign lesions177,16/146,590,31049,66/48,840,9375,08/5,30,764
      NSCLCst.II+IIIa/ benign lesions163,65/146,590,53966,34/48,840,2347,82/5,30,017

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Chemokine values did not differ in NSCLC versus control group. Patients with NSCLC stages II and IIIA had significantly higher CXCL12 concentrations than control group. This could be because CXCL12 promotes tumor growth and metastasis.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Internal grant of Thomayer Hospital.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.